tradingkey.logo

Smith & Nephew PLC

SNN
查看詳細走勢圖
32.845USD
+0.145+0.44%
收盤 12/19, 16:00美東報價延遲15分鐘
14.39B總市值
29.22本益比TTM

Smith & Nephew PLC

32.845
+0.145+0.44%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.44%

5天

+0.66%

1月

+2.67%

6月

+13.93%

今年開始到現在

+33.62%

1年

+33.19%

查看詳細走勢圖

TradingKey Smith & Nephew PLC股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Smith & Nephew PLC當前公司基本面數據相對健康,增長潛力很大。當前估值低估,在醫療設備與耗材行業排名92/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為買入。最高目標價34.16。中期看,股價處於平穩狀態。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Smith & Nephew PLC評分

相關信息

行業排名
92 / 208
全市場排名
217 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 4 分析師
買入
評級
34.157
目標均價
+1.99%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Smith & Nephew PLC亮點

亮點風險
Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
利潤高增長
公司淨利潤處於行業前列,最新年度總收入5.81B美元
高分紅
公司屬於高分紅公司,最新股息支付率79.37%
穩定分紅
公司5年內持續分紅,最新股息支付率79.37%
估值低估
公司最新PE估值29.20,處於3年歷史低位
機構減倉
最新機構持股32.77M股,環比減少26.97%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉14.85K股

Smith & Nephew PLC新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Smith & Nephew PLC簡介

Smith & Nephew plc is a portfolio medical technology company. The Company is engaged in developing, manufacturing, marketing, and selling medical devices and services. It is focused on the repair, regeneration, and replacement of soft and hard tissue. The Company's segments include Orthopaedics, Sports Medicine & ENT and Advanced Wound Management. Its Orthopaedics segment includes a range of hip, knee and shoulder implants used to replace diseased, damaged or worn joints, robotics-assisted enabling technologies that empower surgeons, and trauma products used to stabilise severe fractures and correct bone deformities. Its Sports Medicine & Ear, Nose and Throat (ENT) businesses offer advanced products and instruments used to repair or remove soft tissue. Its Advanced Wound Management portfolio provides a comprehensive set of products to meet broad and complex clinical needs, and to help healthcare professionals reduce the human and economic consequences of wounds.
公司代碼SNN
公司Smith & Nephew PLC
CEONath (Deepak S)
網址https://www.smith-nephew.com/

常見問題

Smith & Nephew PLC(SNN)的當前股價是多少?

Smith & Nephew PLC(SNN)的當前股價是 32.845。

Smith & Nephew PLC 的股票代碼是什麼?

Smith & Nephew PLC的股票代碼是SNN。

Smith & Nephew PLC股票的52週最高點是多少?

Smith & Nephew PLC股票的52週最高點是38.790。

Smith & Nephew PLC股票的52週最低點是多少?

Smith & Nephew PLC股票的52週最低點是23.690。

Smith & Nephew PLC的市值是多少?

Smith & Nephew PLC的市值是14.39B。

Smith & Nephew PLC的淨利潤是多少?

Smith & Nephew PLC的淨利潤為412.00M。

現在Smith & Nephew PLC(SNN)的股票是買入、持有還是賣出?

根據分析師評級,Smith & Nephew PLC(SNN)的總體評級為買入,目標價格為34.157。

Smith & Nephew PLC(SNN)股票的每股收益(EPS TTM)是多少

Smith & Nephew PLC(SNN)股票的每股收益(EPS TTM)是1.124。
KeyAI